Gentian Violet
| ToxCast Endpoints |
|---|
ToxCast Endpoints for intended target type: RNA
| Assay Name | Tissue | Target Gene ID | Target HGNC Symbol | Target UniProt ID | Response | AC50 value |
|---|---|---|---|---|---|---|
| LTEA_HepaRG_ABCC3 | Liver | 8714 | ABCC3 | O15438 | Activatory | 85.76 μM |
| LTEA_HepaRG_AFP | Liver | 174 | AFP | P02771 | Inhibitory | 1.91 μM |
| LTEA_HepaRG_CCND1 | Liver | 595 | CCND1 | P24385 | Inhibitory | 37.08 μM |
| LTEA_HepaRG_CFLAR | Liver | 8837 | CFLAR | O15519 | Inhibitory | 29.61 μM |
| LTEA_HepaRG_CYP1A2 | Liver | 1544 | CYP1A2 | P05177 | Inhibitory | 2.05 μM |
| LTEA_HepaRG_CYP2E1 | Liver | 1571 | CYP2E1 | P05181 | Inhibitory | 2.31 μM |
| LTEA_HepaRG_CYP3A7 | Liver | 1551 | CYP3A7 | P24462 | Inhibitory | 2.16 μM |
| LTEA_HepaRG_DDIT3 | Liver | 1649 | DDIT3 | P35638 | Activatory | 1.38 μM |
| LTEA_HepaRG_EGF | Liver | 1950 | EGF | P01133 | Activatory | 88.81 μM |
| LTEA_HepaRG_EGR1 | Liver | 1958 | EGR1 | P18146 | Inhibitory | 67.64 μM |
| LTEA_HepaRG_EZR | Liver | 7430 | EZR | P15311 | Inhibitory | 31.99 μM |
| LTEA_HepaRG_GADD45A | Liver | 1647 | GADD45A | P24522 | Inhibitory | 50.00 μM |
| LTEA_HepaRG_GCLM | Liver | 2730 | GCLM | P48507 | Inhibitory | 95.33 μM |
| LTEA_HepaRG_HIF1A | Liver | 3091 | HIF1A | Q16665 | Activatory | 44.34 μM |
| LTEA_HepaRG_HSPA1A | Liver | 3303 | HSPA1A | P08107 | Inhibitory | 86.49 μM |
| LTEA_HepaRG_ICAM1 | Liver | 3383 | ICAM1 | P05362 | Activatory | 73.09 μM |
| LTEA_HepaRG_IGF1 | Liver | 3479 | IGF1 | P05019 | Inhibitory | 1.44 μM |
| LTEA_HepaRG_JUN | Liver | 3725 | JUN | P05412 | Inhibitory | 89.21 μM |
| LTEA_HepaRG_LPL | Liver | 4023 | LPL | P06858 | Inhibitory | 36.00 μM |
| LTEA_HepaRG_PDK4 | Liver | 5166 | PDK4 | Q16654 | Inhibitory | 32.41 μM |
| LTEA_HepaRG_STAT3 | Liver | 6774 | STAT3 | P40763 | Inhibitory | 39.35 μM |
| LTEA_HepaRG_TGFB1 | Liver | 7040 | TGFB1 | P01137 | Inhibitory | 68.67 μM |
| LTEA_HepaRG_THRSP | Liver | 7069 | THRSP | Q92748 | Inhibitory | 2.48 μM |
| LTEA_HepaRG_TIMP1 | Liver | 7076 | TIMP1 | P01033 | Inhibitory | 74.24 μM |
ToxCast Endpoints for intended target type: Protein
| Assay Name | Tissue | Target Gene ID | Target HGNC Symbol | Target UniProt ID | Response | AC50 value |
|---|---|---|---|---|---|---|
| CCTE_Deisenroth_5AR_NBTE_ratio | Kidney | 6716 | SRD5A2 | Inhibitory | 0.59 μM | |
| CCTE_GLTED_hTBG | 6906 | SERPINA7 | Loss | 50.00 μM | ||
| ERF_TW_NR_binding_hAR | 367 | AR | P10275 | Gain | 33.80 μM | |
| NVS_ADME_hCYP1A1 | 1543 | CYP1A1 | P04798 | Loss | 2.02 μM | |
| NVS_ENZ_hES | 590 | BCHE | P06276 | Loss | 1.62 μM | |
| NVS_GPCR_h5HT5A | 3361 | HTR5A | P47898 | Loss | 1.99 μM | |
| NVS_GPCR_hAdra2A | 150 | ADRA2A | P08913 | Loss | 2.59 μM | |
| NVS_GPCR_hAdra2C | 152 | ADRA2C | P18825 | Loss | 1.79 μM | |
| NVS_GPCR_hDRD1 | 1812 | DRD1 | P21728 | Loss | 1.94 μM | |
| NVS_GPCR_hDRD2s | 1813 | DRD2 | P14416 | Loss | 2.02 μM | |
| NVS_GPCR_hDRD4.4 | 1815 | DRD4 | P21917 | Loss | 1.11 μM | |
| NVS_GPCR_hETA | 1909 | EDNRA | P25101 | Loss | 1.81 μM | |
| NVS_GPCR_hM1 | 1128 | CHRM1 | P11229 | Loss | 1.91 μM | |
| NVS_GPCR_hM2 | 1129 | CHRM2 | P08172 | Loss | 0.94 μM | |
| NVS_GPCR_hM4 | 1132 | CHRM4 | P08173 | Loss | 0.86 μM | |
| NVS_GPCR_hM5 | 1133 | CHRM5 | P08912 | Loss | 0.86 μM | |
| NVS_GPCR_hOpiate_mu | 4988 | OPRM1 | P35372 | Loss | 2.50 μM | |
| NVS_MP_hPBR | Intestinal | 706 | TSPO | P30536 | Loss | 1.40 μM |
| NVS_NR_hGR | 2908 | NR3C1 | P04150 | Loss | 1.87 μM | |
| ATG_AP_1_CIS | Liver | 3725|2353 | JUN|FOS | P01100|P05412 | Activatory | 2.23 μM |
| ATG_DR5_RAR_CIS | Liver | 5916|5915|5914 | RARG|RARB|RARA | P10826|P10276|P13631 | Inhibitory | 2.58 μM |
| ATG_EGR_CIS | Liver | 1958 | EGR1 | P18146 | Activatory | 2.23 μM |
| ATG_ERE_CIS | Liver | 2099 | ESR1 | P03372 | Activatory | 1.01 μM |
| ATG_ISRE_CIS | Liver | 3659 | IRF1 | P10914 | Inhibitory | 2.28 μM |
| ATG_M_32_CIS | Liver | Activatory | 2.03 μM | |||
| ATG_NRF2_ARE_CIS | Liver | 4780 | NFE2L2 | Q16236 | Activatory | 2.43 μM |
| ATG_p53_CIS | Liver | 7157 | TP53 | P04637 | Inhibitory | 1.08 μM |
| ATG_PXRE_CIS | Liver | 8856 | NR1I2 | O75469 | Inhibitory | 2.19 μM |
| ATG_Sp1_CIS | Liver | 6667 | SP1 | P08047 | Activatory | 1.69 μM |
| ATG_TA_CIS | Liver | Activatory | 0.99 μM | |||
| ATG_Xbp1_CIS | Liver | 7494 | XBP1 | P17861 | Activatory | 2.28 μM |
| BSK_3C_Eselectin | Vascular | 6401 | SELE | P16581 | Inhibitory | 0.82 μM |
| BSK_3C_HLADR | Vascular | 3122 | HLA-DRA | P01903 | Inhibitory | 0.34 μM |
| BSK_3C_MCP1 | Vascular | 6347 | CCL2 | P13500 | Inhibitory | 0.80 μM |
| BSK_3C_uPAR | Vascular | 5329 | PLAUR | Q03405 | Inhibitory | 0.78 μM |
| BSK_4H_Eotaxin3 | Vascular | 10344 | CCL26 | Q9Y258 | Inhibitory | 1.17 μM |
| BSK_4H_MCP1 | Vascular | 6347 | CCL2 | P13500 | Inhibitory | 0.66 μM |
| BSK_4H_Pselectin | Vascular | 6403 | SELP | P16109 | Inhibitory | 0.61 μM |
| BSK_4H_uPAR | Vascular | 5329 | PLAUR | Q03405 | Inhibitory | 1.42 μM |
| BSK_4H_VEGFRII | Vascular | 3791 | KDR | P35968 | Inhibitory | 0.15 μM |
| BSK_BE3C_HLADR | Lung | 3122 | HLA-DRA | P01903 | Inhibitory | 1.28 μM |
| BSK_BE3C_IL1a | Lung | 3552 | IL1A | P01583 | Inhibitory | 2.36 μM |
| BSK_BE3C_MMP1 | Lung | 4312 | MMP1 | P03956 | Inhibitory | 0.94 μM |
| BSK_BE3C_PAI1 | Lung | 5054 | SERPINE1 | P05121 | Inhibitory | 0.23 μM |
| BSK_BE3C_TGFb1 | Lung | 7040 | TGFB1 | P01137 | Inhibitory | 0.73 μM |
| BSK_BE3C_tPA | Lung | 5327 | PLAT | P00750 | Inhibitory | 1.19 μM |
| BSK_BE3C_uPA | Lung | 5328 | PLAU | P00749 | Inhibitory | 1.97 μM |
| BSK_CASM3C_MCP1 | Vascular | 6347 | CCL2 | P13500 | Inhibitory | 1.07 μM |
| BSK_CASM3C_SAA | Vascular | 6288 | SAA1 | P0DJI8 | Inhibitory | 0.82 μM |
| BSK_CASM3C_TissueFactor | Vascular | 2152 | F3 | P13726 | Inhibitory | 1.49 μM |
| BSK_CASM3C_uPAR | Vascular | 5329 | PLAUR | Q03405 | Inhibitory | 1.54 μM |
| BSK_hDFCGF_CollagenIII | Skin | 1281 | COL3A1 | P02461 | Inhibitory | 0.15 μM |
| BSK_hDFCGF_MCSF | Skin | 1435 | CSF1 | P09603 | Inhibitory | 1.77 μM |
| BSK_hDFCGF_PAI1 | Skin | 5054 | SERPINE1 | P05121 | Inhibitory | 1.54 μM |
| BSK_hDFCGF_SRB | Skin | Inhibitory | 2.00 μM | |||
| BSK_hDFCGF_TIMP1 | Skin | 7076 | TIMP1 | P01033 | Inhibitory | 1.95 μM |
| BSK_KF3CT_IL1a | Skin | 3552 | IL1A | P01583 | Inhibitory | 2.54 μM |
| BSK_KF3CT_MMP9 | Skin | 4318 | MMP9 | P14780 | Inhibitory | 1.33 μM |
| BSK_KF3CT_TGFb1 | Skin | 7040 | TGFB1 | P01137 | Inhibitory | 0.59 μM |
| BSK_KF3CT_TIMP2 | Skin | 7077 | TIMP2 | Q96MC4 | Inhibitory | 1.29 μM |
| BSK_LPS_CD40 | Vascular | 958 | CD40 | P25942 | Inhibitory | 0.44 μM |
| BSK_LPS_Eselectin | Vascular | 6401 | SELE | P16581 | Inhibitory | 0.36 μM |
| BSK_LPS_IL1a | Vascular | 3552 | IL1A | P01583 | Inhibitory | 0.15 μM |
| BSK_LPS_IL8 | Vascular | 3576 | CXCL8 | P10145 | Inhibitory | 1.26 μM |
| BSK_LPS_MCP1 | Vascular | 6347 | CCL2 | P13500 | Inhibitory | 0.27 μM |
| BSK_LPS_MCSF | Vascular | 1435 | CSF1 | P09603 | Inhibitory | 0.48 μM |
| BSK_LPS_PGE2 | Vascular | 5732 | PTGER2 | P43116 | Inhibitory | 1.13 μM |
| BSK_LPS_TissueFactor | Vascular | 2152 | F3 | P13726 | Inhibitory | 0.66 μM |
| BSK_LPS_TNFa | Vascular | 7124 | TNF | P01375 | Inhibitory | 1.46 μM |
| BSK_LPS_VCAM1 | Vascular | 7412 | VCAM1 | P19320 | Inhibitory | 2.51 μM |
| BSK_SAg_CD38 | Vascular | 952 | CD38 | P28907 | Inhibitory | 1.01 μM |
| BSK_SAg_CD40 | Vascular | 958 | CD40 | P25942 | Inhibitory | 0.53 μM |
| BSK_SAg_CD69 | Vascular | 969 | CD69 | Q07108 | Inhibitory | 0.58 μM |
| BSK_SAg_Eselectin | Vascular | 6401 | SELE | P16581 | Inhibitory | 0.22 μM |
| BSK_SAg_IL8 | Vascular | 3576 | CXCL8 | P10145 | Inhibitory | 0.15 μM |
| BSK_SAg_MCP1 | Vascular | 6347 | CCL2 | P13500 | Inhibitory | 0.33 μM |
| BSK_SAg_MIG | Vascular | 4283 | CXCL9 | Q07325 | Inhibitory | 1.61 μM |
| NVS_ENZ_hVEGFR2 | 3791 | KDR | P35968 | Loss | 0.57 μM | |
| NVS_NR_hPPARg | 5468 | PPARG | P37231 | Loss | 1.40 μM | |
| STM_H9_CystineISnorm_perc | Activatory | 0.82 μM | ||||
| STM_H9_OrnithineISnorm_perc | Inhibitory | 0.59 μM | ||||
| STM_H9_OrnCyssISnorm_ratio | Inhibitory | 0.72 μM | ||||
| CCTE_GLTED_hDIO2 | 1734 | DIO2 | Loss | 133.70 μM | ||
| TOX21_AR_BLA_Antagonist_ratio | Kidney | 367 | AR | P10275 | Loss | 1.33 μM |
| TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881 | Breast | 367 | AR | P10275 | Loss | 2.29 μM |
| TOX21_VDR_BLA_Antagonist_ch1 | Kidney | Gain | 27.80 μM | |||
| TOX21_VDR_BLA_Antagonist_ch2 | Kidney | Loss | 29.13 μM | |||
| TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881 | Breast | 367 | AR | P10275 | Loss | 1.92 μM |
| TOX21_ERR_LUC_Antagonist | Kidney | 2101 | ESRRA | P11474 | Loss | 0.70 μM |
| TOX21_PGC_ERR_LUC_Antagonist | Kidney | 2101 | ESRRA | P11474 | Loss | 0.68 μM |
| TOX21_SBE_BLA_Agonist_ratio | Kidney | 4086 | SMAD1 | Q15797 | Gain | 29.79 μM |
| TOX21_AR_BLA_Antagonist_ratio | Kidney | 367 | AR | P10275 | Loss | 0.28 μM |
| TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881 | Breast | 367 | AR | P10275 | Loss | 1.73 μM |
| TOX21_Aromatase_LUC_Antagonist | Breast | 1588 | CYP19A1 | P11511 | Loss | 0.75 μM |
| TOX21_GR_BLA_Agonist_ratio | Cervix | 2908 | NR3C1 | P04150 | Gain | 59.52 μM |
| TOX21_VDR_BLA_Antagonist_ch2 | Kidney | Loss | 29.40 μM | |||
| TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881 | Breast | 367 | AR | P10275 | Loss | 1.60 μM |
| TOX21_TSHR_HTRF_Antagonist_ratio | Kidney | 7253 | TSHR | Loss | 55.33 μM | |
| TOX21_CAR_LUC_Antagonist | Liver | 9970 | NR1I3 | Q14994 | Loss | 30.43 μM |
| TOX21_ERR_LUC_Antagonist | Kidney | 2101 | ESRRA | P11474 | Loss | 0.90 μM |
| TOX21_PGC_ERR_LUC_Antagonist | Kidney | 2101 | ESRRA | P11474 | Loss | 0.68 μM |
| TOX21_ERb_BLA_Antagonist_ratio | Kidney | 2100 | ESR2 | Q92731 | Loss | 31.70 μM |
| TOX21_AChE_Colorimetric_Antagonist | Bone | 43 | ACHE | P22303 | Loss | 74.28 μM |
| TOX21_PXR_LUC_Agonist | Liver | 8856 | NR1I2 | O75469 | Gain | 0.91 μM |
| TOX21_AChE_Antagonist | 43 | ACHE | P22303 | Loss | 47.54 μM | |
| TOX21_AR_BLA_Agonist_ratio | Kidney | 367 | AR | P10275 | Gain | 32.02 μM |
| TOX21_AR_BLA_Antagonist_ratio | Kidney | 367 | AR | P10275 | Loss | 0.39 μM |
| TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881 | Breast | 367 | AR | P10275 | Loss | 1.14 μM |
| TOX21_Aromatase_LUC_Antagonist | Breast | 1588 | CYP19A1 | P11511 | Loss | 0.87 μM |
| TOX21_ERa_BLA_Agonist_ratio | Kidney | 2099 | ESR1 | P03372 | Gain | 30.18 μM |
| TOX21_ERa_BLA_Antagonist_ratio | Kidney | 2099 | ESR1 | P03372 | Loss | 0.29 μM |
| TOX21_GR_BLA_Agonist_ratio | Cervix | 2908 | NR3C1 | P04150 | Gain | 62.30 μM |
| TOX21_TSHR_HTRF_Antagonist_ratio | Kidney | 7253 | TSHR | Loss | 46.08 μM | |
| TOX21_CAR_LUC_Antagonist | Liver | 9970 | NR1I3 | Q14994 | Loss | 45.15 μM |
| TOX21_ERR_LUC_Antagonist | Kidney | 2101 | ESRRA | P11474 | Loss | 1.16 μM |
| TOX21_PGC_ERR_LUC_Antagonist | Kidney | 2101 | ESRRA | P11474 | Loss | 1.10 μM |
| TOX21_SBE_BLA_Antagonist_ch2 | Kidney | Loss | 53.09 μM | |||
| TOX21_SBE_BLA_Antagonist_ratio | Kidney | 4086 | SMAD1 | Q15797 | Loss | 50.62 μM |
| TOX21_AChE_Antagonist | 43 | ACHE | P22303 | Loss | 41.95 μM | |
| TOX21_hERG_U2OS_Antagonist | Bone | 3757 | KCNH2 | Q12809 | Loss | 2.10 μM |
No ToxCast endpoints for intended target type: Molecular Messengers
ToxCast Endpoints for intended target type: Pathway
| Assay Name | Tissue | Target Gene ID | Target HGNC Symbol | Target UniProt ID | Response | AC50 value |
|---|---|---|---|---|---|---|
| UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist | Bone | 367 | AR | P10275 | Loss | 0.26 μM |
| APR_HepG2_CellCycleArrest_24hr | Liver | Inhibitory | 0.75 μM | |||
| APR_HepG2_CellCycleArrest_72hr | Liver | Inhibitory | 0.41 μM | |||
| APR_HepG2_StressKinase_72hr | Liver | 3725 | JUN | P05412 | Activatory | 40.02 μM |
| OT_AR_ARSRC1_0960 | Kidney | 6714|367 | AR|SRC | P12931|P10275 | Gain | 0.27 μM |
| ACEA_AR_antagonist_80hr | Prostate | 367 | AR | P10275 | Loss | 0.17 μM |
| TOX21_ERa_BLA_Antagonist_ch1 | Kidney | Gain | 1.55 μM | |||
| TOX21_ERa_BLA_Antagonist_ch2 | Kidney | Loss | 35.98 μM | |||
| TOX21_AR_BLA_Antagonist_ch2 | Kidney | Loss | 1.47 μM | |||
| TOX21_p53_BLA_p4_ratio | Intestinal | 7157 | TP53 | P04637 | Gain | 30.77 μM |
| TOX21_HRE_BLA_Agonist_ch1 | Cervix | Loss | 32.36 μM | |||
| TOX21_GR_BLA_Agonist_ch1 | Cervix | Loss | 29.60 μM | |||
| TOX21_p53_BLA_p1_ratio | Intestinal | 7157 | TP53 | P04637 | Gain | 45.70 μM |
| TOX21_FXR_BLA_Agonist_ch1 | Kidney | Loss | 67.56 μM | |||
| TOX21_FXR_BLA_Agonist_ratio | Kidney | 9971 | NR1H4 | Q96RI1 | Gain | 68.72 μM |
| TOX21_PPARd_BLA_Agonist_ch1 | Kidney | Loss | 61.26 μM | |||
| TOX21_PPARd_BLA_Agonist_ratio | Kidney | 5467 | PPARD | Q03181 | Gain | 60.02 μM |
| TOX21_FXR_BLA_Antagonist_ch2 | Kidney | Loss | 33.26 μM | |||
| TOX21_PPARd_BLA_Antagonist_ch2 | Kidney | Loss | 30.63 μM | |||
| TOX21_AR_BLA_Antagonist_ch2 | Kidney | Loss | 0.72 μM | |||
| TOX21_p53_BLA_p2_ratio | Intestinal | 7157 | TP53 | P04637 | Gain | 32.81 μM |
| TOX21_p53_BLA_p3_ratio | Intestinal | 7157 | TP53 | P04637 | Gain | 31.50 μM |
| TOX21_p53_BLA_p4_ratio | Intestinal | 7157 | TP53 | P04637 | Gain | 51.70 μM |
| TOX21_p53_BLA_p5_ratio | Intestinal | 7157 | TP53 | P04637 | Gain | 33.96 μM |
| TOX21_ESRE_BLA_Agonist_ch1 | Cervix | Loss | 59.58 μM | |||
| TOX21_NFkB_BLA_agonist_ch1 | Cervix | Loss | 38.16 μM | |||
| TOX21_HRE_BLA_Agonist_ratio | Cervix | 3091 | HIF1A | Q16665 | Gain | 30.23 μM |
| TOX21_ERb_BLA_Antagonist_ch2 | Kidney | Loss | 31.03 μM | |||
| TOX21_AR_BLA_Agonist_ch1 | Kidney | Loss | 35.64 μM | |||
| TOX21_ARE_BLA_Agonist_ratio | Liver | 4780 | NFE2L2 | Q16236 | Gain | 0.94 μM |
| TOX21_HSE_BLA_Agonist_ch1 | Cervix | Loss | 38.31 μM | |||
| TOX21_HSE_BLA_Agonist_ratio | Cervix | 3297 | HSF1 | Q00613 | Gain | 38.31 μM |
| TOX21_p53_BLA_p1_ch1 | Intestinal | Loss | 28.56 μM | |||
| TOX21_p53_BLA_p1_ratio | Intestinal | 7157 | TP53 | P04637 | Gain | 64.12 μM |
| TOX21_AR_BLA_Antagonist_ch2 | Kidney | Loss | 0.68 μM | |||
| TOX21_p53_BLA_p2_ratio | Intestinal | 7157 | TP53 | P04637 | Gain | 33.57 μM |
| TOX21_p53_BLA_p3_ch1 | Intestinal | Loss | 34.57 μM | |||
| TOX21_p53_BLA_p4_ch1 | Intestinal | Loss | 30.27 μM | |||
| TOX21_p53_BLA_p4_ratio | Intestinal | 7157 | TP53 | P04637 | Gain | 52.49 μM |
| TOX21_p53_BLA_p5_ratio | Intestinal | 7157 | TP53 | P04637 | Gain | 47.34 μM |
| TOX21_ESRE_BLA_Agonist_ch1 | Cervix | Loss | 65.27 μM | |||
| TOX21_NFkB_BLA_agonist_ch1 | Cervix | Loss | 60.85 μM | |||
| TOX21_HRE_BLA_Agonist_ch1 | Cervix | Loss | 58.96 μM | |||
| TOX21_HRE_BLA_Agonist_ratio | Cervix | 3091 | HIF1A | Q16665 | Gain | 62.97 μM |
| TOX21_ERb_BLA_Antagonist_ch2 | Kidney | Loss | 84.70 μM |
ToxCast Endpoints for intended target type: Cellular
| Assay Name | Tissue | Response | AC50 value |
|---|---|---|---|
| CCTE_Simmons_MITO_basal_resp_rate | Liver | Activatory | 50.00 μM |
| CCTE_Simmons_MITO_max_resp_rate | Liver | Activatory | 41.57 μM |
| CCTE_Simmons_MITO_inhib_resp_rate | Liver | Activatory | 61.63 μM |
| APR_HepG2_MitoMass_72hr | Liver | Inhibitory | 0.04 μM |
| APR_HepG2_MitoMembPot_72hr | Liver | Inhibitory | 0.38 μM |
| BSK_3C_Proliferation | Vascular | Inhibitory | 2.42 μM |
| BSK_CASM3C_Proliferation | Vascular | Inhibitory | 2.06 μM |
| BSK_hDFCGF_Proliferation | Skin | Inhibitory | 1.39 μM |
| BSK_SAg_Proliferation | Vascular | Inhibitory | 0.69 μM |
| CCTE_Simmons_CellTiterGLO_HEK293T | Kidney | Loss | 0.95 μM |
| STM_H9_NormalizedViability | Loss | 0.77 μM | |
| ACEA_AR_agonist_AUC_viability | Prostate | Loss | 0.28 μM |
| ACEA_AR_antagonist_AUC_viability | Prostate | Loss | 0.16 μM |
| TOX21_MMP_rhodamine | Liver | Loss | 0.16 μM |
| TOX21_MMP_ratio | Liver | Inhibitory | 0.14 μM |
| TOX21_NFkB_BLA_agonist_viability | Cervix | Loss | 29.02 μM |
| TOX21_HRE_BLA_Agonist_viability | Cervix | Loss | 29.56 μM |
| TOX21_RT_HEK293_GLO_32hr_viability | Kidney | Loss | 1.20 μM |
| TOX21_RT_HEK293_GLO_40hr_viability | Kidney | Loss | 1.00 μM |
| TOX21_AR_BLA_Antagonist_viability | Kidney | Loss | 1.10 μM |
| TOX21_GR_BLA_Antagonist_viability | Cervix | Loss | 2.26 μM |
| TOX21_MMP_rhodamine | Liver | Loss | 0.06 μM |
| TOX21_MMP_viability | Liver | Loss | 54.28 μM |
| TOX21_PPARg_BLA_Antagonist_viability | Kidney | Loss | 1.74 μM |
| TOX21_MMP_ratio | Liver | Inhibitory | 0.06 μM |
| TOX21_RT_HEK293_GLO_40hr_viability | Kidney | Loss | 2.20 μM |
| TOX21_RT_HEPG2_GLO_16hr_viability | Liver | Loss | 31.43 μM |
| TOX21_RT_HEPG2_GLO_32hr_viability | Liver | Loss | 31.71 μM |
| TOX21_RT_HEPG2_GLO_40hr_viability | Liver | Loss | 31.85 μM |
| TOX21_AR_BLA_Antagonist_viability | Kidney | Loss | 0.57 μM |
| TOX21_ELG1_LUC_Agonist_viability | Kidney | Loss | 28.83 μM |
| TOX21_MMP_rhodamine | Liver | Loss | 0.07 μM |
| TOX21_MMP_viability | Liver | Loss | 72.57 μM |
| TOX21_PPARg_BLA_Antagonist_viability | Kidney | Loss | 2.18 μM |
| TOX21_p53_BLA_p1_viability | Intestinal | Loss | 31.16 μM |
| TOX21_p53_BLA_p3_viability | Intestinal | Loss | 56.61 μM |
| TOX21_p53_BLA_p4_viability | Intestinal | Loss | 28.75 μM |
| TOX21_p53_BLA_p5_viability | Intestinal | Loss | 46.08 μM |
| TOX21_NFkB_BLA_agonist_viability | Cervix | Loss | 60.24 μM |
| TOX21_RXR_BLA_Agonist_viability | Kidney | Loss | 30.81 μM |
| TOX21_AP1_BLA_Agonist_viability | Cervix | Loss | 51.78 μM |
| TOX21_MMP_ratio | Liver | Inhibitory | 0.07 μM |
| TOX21_HRE_BLA_Agonist_viability | Cervix | Loss | 51.65 μM |
| TOX21_RT_HEK293_FLO_40hr_viability | Kidney | Gain | 38.31 μM |
| TOX21_RT_HEK293_GLO_08hr_viability | Kidney | Loss | 38.31 μM |
| TOX21_RT_HEK293_GLO_24hr_viability | Kidney | Loss | 1.67 μM |
| TOX21_RT_HEK293_GLO_32hr_viability | Kidney | Loss | 1.76 μM |
| TOX21_RT_HEK293_GLO_40hr_viability | Kidney | Loss | 2.15 μM |
| TOX21_RT_HEPG2_GLO_32hr_viability | Liver | Loss | 28.78 μM |
| TOX21_RT_HEPG2_GLO_40hr_viability | Liver | Loss | 34.13 μM |
| TOX21_PR_BLA_Agonist_viability | Kidney | Loss | 42.87 μM |
| TOX21_PR_BLA_Antagonist_viability | Kidney | Loss | 32.38 μM |
| TOX21_PXR_LUC_Agonist_viability | Liver | Loss | 2.26 μM |
| TOX21_SBE_BLA_Antagonist_viability | Kidney | Loss | 31.75 μM |
| TOX21_SBE_BLA_Agonist_viability | Kidney | Loss | 38.31 μM |
ToxCast Endpoints for intended target type: Extracellular
| Assay Name | Tissue | Response | AC50 value |
|---|---|---|---|
| TAMU_PeakParms_SingleDonor1434_QT | Heart | Gain | 0.35 μM |
| TAMU_PeakParms_SingleDonor1434_Asystole | Heart | Loss | 0.59 μM |
DISCLAIMER
TICToK is a database of tattoo ink chemicals compiled from different regulatory resources. The authors are not liable for any inaccuracies or omissions of any chemicals in this resource. Importantly, our sole goal to build this resource on tattoo ink chemicals is to enable future basic research on this topic, and it does not necessarily reflect the views or objectives of our employers or funders.